The Newsroom

Sai Life Sciences partnered with a leading U.S. Big Pharma company to optimize and scale a highly sensitive C‑terminal peptide containing six stereocenters. The objective was to enhance stage-wise yields, eliminate chromatography in the final step, and ensure high-purity API supply through late-stage clinical development.

Sai Life Sciences partnered with a long-standing U.S. biotech client to optimize a complex 11‑step synthesis for a sensitive, chiral non‑natural peptide. The aim was to improve yield, streamline manufacturing, and ensure reliable API supply for early clinical studies.